PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Financial Statements and Exhibits

PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

Story continues below

(d) Exhibits.

Exhibit No. Description
99.1 Press release, dated September 20, 2017

EX-99.1 2 v475490_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency   PhaseRx’s second enzyme replacement therapy to receive orphan drug designation for a Urea Cycle Disorder   SEATTLE,…
To view the full exhibit click here

About PhaseRx, Inc. (NASDAQ:PZRX)

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

An ad to help with our costs